PHR:NYE-Phreesia Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 28.43

Change

-0.13 (-0.46)%

Market Cap

N/A

Volume

0.37M

Analyst Target

USD 30.11
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-12 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

+0.03 (+0.04%)

USD 13.01B
DOCS Doximity Inc

+0.24 (+0.32%)

USD 11.03B
WEAV Weave Communications Inc

-0.14 (-0.81%)

USD 1.25B
MPLN MultiPlan Corporation

+3.03 (+12.63%)

USD 0.30B
AMWL American Well Corp

+0.88 (+7.67%)

USD 0.18B
OWLT Owlet Inc

-0.10 (-2.09%)

USD 0.08B
TDOC Teladoc Inc

-0.49 (-3.76%)

N/A
FOXO FOXO Technologies Inc.

N/A

N/A
EVH Evolent Health Inc

-0.26 (-2.64%)

N/A
VEEV Veeva Systems Inc Class A

-0.99 (-0.42%)

N/A

ETFs Containing PHR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.00% 64% D 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.00% 64% D 92% A
Trailing 12 Months  
Capital Gain 4.25% 70% C- 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.25% 70% C- 34% F
Trailing 5 Years  
Capital Gain -12.82% 75% C 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.82% 75% C 19% F
Average Annual (5 Year Horizon)  
Capital Gain 8.26% 70% C- 61% D-
Dividend Return 8.26% 70% C- 54% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 64.26% 70% C- 14% F
Risk Adjusted Return 12.86% 80% B- 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector